Grants

Present Support

2014 - 2019
Complement in inflammatory diseases: Mechanisms & therapeutic modulation NIH P01-AI068730 
Total Support $10,000,000
(Priority Score 1)

2013 - 2017
Disarming the intravascular innate immune response to improve modalities for chronic kidney disease treatment DIREKT (FP7-HEALTH-2013-INNOVATION-1)
EUROPEAN GRANT
PI: B Nilsson; Co-PI: JD Lambris
Total Support for JD Lambris: $1,000,000

2013 - 2017
Structural analysis of the tird component of complement NIH AI 30040
Total Support $1,471,833

2012 - 2016
Novel mechanisms and Complement-ary therapy in periodontitis NIH DE021685 
PI: G Hajishengalis; Co-PI: JD Lambris
Total Support: $2,000,000

2012 - 2015
 A novel approach for assessing dynamic events in the human complement system NIH R21-AI097805
PI: D. Ricklin; Co-PI: John D. Lambris
Total Support: $676,800

2011 - 2016
Complement inhibition as sepsis therapy
NIH 1-R01-GM-097747-01
M.P.I. JD Lambris & F Lupu (University of Oklahoma)
Total Support $2,084,220

2011 - 2015
Complement in AMD: Mechanisms and therapeutic intervention
NIH 5-R01-EY-020633



 

Past Grants

2012 - 2013
  
Complement based therapies to periodontal disease
ITMAT Univeristy of Pennsylvania UL1RR024134
2011 - 2012
  
A novel iron-amyloid beta pathway for complement activation quantified with a new high sensitivity assay
Beckman Foundation (Arnold and Mabel) (P.I. Dunaief, Joshua L University of Pennsylvania)

2007 - 2012
  
Complement in cell proliferation and injury - therapeutic interventions NIH effort 40%. Total Support $7,500,000 (Priority Score 154)
2007 - 2012
  
Complement mediated neuronal injury in stroke NIH (P.I.Connely, Columbia University), effort 5%. Total Support for JDL $634,000.

2007 - 2012
  
Design of novel complement inhibitors NIH Total Support $1,260,000 (Priority Score 127, 7.7 Percentile)
2007 - 2012
  
Structural functional analysis of staphylococcal complement inhibitors NIH (P.I.Geisbrecht, B University of Missouri-Kansas City), Total Support for JDL $780,000 (9.9 Percentile)

2007 - 2012
  
Thermodynamic and structural studies on formation of the C3 convertase NIH effort 10%. Total Support $1,981,250 (2.9 Percentile)
2006 - 2012
  
Structural and functional analysis of C3 NIH AI 30040 Total Support $1,631,875 (2 Percentile)

2005 - 2010
  
Biomaterial-induced complement activation NIH Total Support $1,064,213 (12.7 Percentile)
2005 - 2010
  
The role of complement in ovarian cancer NIH Total Support $1,585.000 (3.6 Percentile)

2004 - 2008
  
Computer aided design of complement therapeutics NIH R24GM069736 Total Support $1,871,000 (Priority Score 127, 7.7 Percentile)
2004 - 2007
  
In Silico De Novo protein design: A Dynamically Data Driven, (DDDAS), Computational and experimental framework ITR:Collaborative Research: (ASE+NHS+EVS)-(sim+dmc+int) NSF 0426691 (P.I.Floudas, C. Princeton), effort 10%. Total Support for JDL $370,000.

2003 - 2007
  
Defence against biowarfare and emerging infection agents. Sub project 3 of poxvirus project: Indentify the targets of VIG using proteomics approach NIH U54 AI057168-01 effort 10%. Total Support $720,000
2001 - 2007
  
Structural-functional analysis of Compstatin NIH GM-62134 Total Support $1,300,000. (9.9 Percentile)

2001 - 2006
  
Vaccinia B5R protein in spread immune evasion, vaccines NIH (P.I.Isaacs, S), effort 5%. Total Support for JDL $395,500
2000 - 2006
  
Structural and functional analysis of C3 NIH AI 30040 Total Support $1,193,000

2000 - 2004
  
Poxvirus SCR-containing proteins as therapeutic targets NIH (P.I.Isaacs, S), effort 5%. Total Support for JDL $521,500
1999
  
Purchase of a MALDI/MS system NIH Total Support $250,000

1998 - 2003
  
Role of B cells in autoimmune diabetes NIH (P.I.Naji, A), effort 5%. Total Support for JDL $324,320
1998 - 2003
  
Studies on complement diversity and evolution NIH GM-56698 effort %10. Total Support $1,231,877

1997 - 2003
  
Pathogenesis of persistent viral injury to the CNS-Sub: Early events in herpes simple virus entry into cells of neural origin. NIH (P.I.Eisenberg, R), effort 5% Total Support for JDL $160,000
1997 - 2002
  
Cellular interactions of plasma proteins. NIH P-10-HL-56914 (P.I.Walsh, P), effort 10% Total Support for JDL $688,000

1997 - 2002
  
Early events in Herpes Simplex Virus Entry. NIH (P.I.Eisenberg, R), effort 5% Total Support for JDL $159,000
1997
  
Purchase of an HPLC system Research Foundation of the University of Pennsylvania Total Support $14,500

1996 - 2001
  
Virus and immune injury to vessel wall cells NIH 5 RO1 HL28220 effort 10%. Total Support $625,770
1995 - 1999
  
CSVTCG-Specific thrombospondin receptor in breast cancer NIH CA65675 (P.I.Tuszynski, G), effort 10%. Total Support for JDL $379,624

1995
  
Purchase of multiple peptide synthesizer Research Foundation of the University of Pennsylvania Total Support $32,000
1994 - 1997
  
Structural and functional analysis of complement proteins from different species NSF MCB-9319111 Total Support $300,000

1993 - 1998
  
Structural and functional analysis of C3 from different species NIH AI 30040 Total Support $1,124,199
1992 - 1995
  
Peritoneal macrophage migration in endometriosis NIH HD 30475 (P.I.Coutifaris, C), effort 10%. Total Support for JDL $297,241

1991 - 2002
  
Support Grant University of Pennsylvania Diabetes Center 2P30-DK-19525 (P.I.Matschinsky, F), effort 10%. Total Support for JDL $480,625
1991 - 1994
  
Structural and functional analysis of chicken and lamprey C3 NSF DCB-9018751 Total Support $300,000

1991 - 1992
  
Research Grant Research Foundation of the University of Pennsylvania URF-3-71696 Total Support $12,000
1990 - 1991
  
Structural analysis of C3d/EBV-CR2 interactions American Cancer Society IN-135K Total Support 10,000

1989 - 2001
  
Support Grant University of Pennsylvania Cancer Center 5P30-CA-16520 (P.I.Glick, J), effort 10%. Total Support for JDL $710,000
1984 - 1987
  
Research Grant NIH 1R01-AI21014 Total Support $320,000

1982 - 1984
  
New Investigator Award NIH IR23-AI-18546 Total Support $180,000
1982 - 1982
  
Research Grant American Cancer Society IM-308 Total Support $140,000